KLI
Login
OAK 국가리포지터리
검색
Community
Titles
Authors
Keyword
Issue Date
Ulsan Univ. Repository
Browsing by Author : Myung-Ju Ahn
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
가
나
다
라
마
바
사
아
자
차
카
타
파
하
All
가
나
다
라
마
바
사
아
자
차
카
타
파
하
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or enter first few letters:
Sort by:
title
issue date
submit date
In order:
Ascending
Descending
Results/Page
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
Etal:
All
1
3
5
10
15
20
25
30
35
40
45
50
Showing results 1 to 9 of 9
1
Article
A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors
Byoung Chul Cho
;
Ji-Youn Han
;
Sang-We Kim
;
et al
2022
2
Article
Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer
이대호
;
Adnan Nagrial
;
Byoung Chul Cho
;
et al
2021
3
Article
Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
김성배
;
Bhumsuk Keam
;
Ho Jung An
;
et al
2020
4
Article
Lung Cancer in Korea
송시열
;
최창민
;
Ho Yun Lee
;
et al
2021
5
Article
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
김상위
;
Anders Mellemgaard
;
Byoung Chul Cho
;
et al
2020
6
Article
Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea
김상위
;
Bong-Seog Kim
;
Byoung Chul Cho
;
et al
2020
7
Article
Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
김상위
;
민영주
;
Byoung-Yong Shim
;
et al
2021
8
Article
Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
Morihito Okada
;
Ken Kato
;
Byoung Chul Cho
;
et al
2022
9
Article
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
김성배
;
Alan L Ho
;
Antonio Gualberto
;
et al
2021
1
Anonymous
Login
Community
Titles
Authors
Keyword
Issue Date
Guide